Keyword: Merck KGaA

Merck KGaA has licensed a cloud-based artificial intelligence proteome screening platform from the Toronto-based Cyclica.

Xenotransplantation firm eGenesis hires new R&D head; Relay adds execs to chemistry, R&D; and Navidea brings on new CMO focused on imaging.

Merck KGaA is launching a new joint venture with the tech firm Palantir, built around a collaboration platform for cancer research and discovery.

Roche’s Rituxan and an anti-CD47 drug from Stanford shrank the cancers of half the patients in a phase 1 trial.

Merck KGaA has tapped digital diabetes platform provider GlucoMe for a pilot collaboration in five hospitals across Vietnam.

ApoGen raised $4 million with help from Merck KGaA's M Ventures, and hired Stephen Gwaltney as chemistry VP and Peter de Vries as biology director.

Principia Biopharma has filed to raise up to $86.3 million in its IPO to carry its lead BTK inhibitor into phase 3.

MilliporeSigma and InnoCore will work to offer a delivery platform for sustained-release formulations for “virtually any” injectable biologic.

Vaccinex filed a $46 million Nasdaq IPO to support its development of antibodies and conjugates targeting neurodegenerative diseases and cancer.

The Temasek-led series C round comes five months after Akili posted positive data from a pivotal clinical trial of its digital medicine.